OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
February 03, 2023
Topical eye treatments can be beneficial for patients with a growing array of eye diseases, but only if taken appropriately.
Shifting guidance and the growing prominence of computer software assurance exemplify the state of computer software validation.
February 02, 2023
In vivo CAR-T gene therapies could resolve challenges faced by autologous and allogeneic treatments.
This new pioneering phase of mRNA is loaded with potential, but also obstacles and false dawns.
January 30, 2023
This event is now available on-demand!
January 25, 2023
Webinar Date/Time: Tuesday, February 21st, 2023 at 11am EST | 8am PST | 4pm GMT | 5pm CET
January 18, 2023
Recently, 2seventy bio announced the initiation of a strategic partnership with JW Therapeutics aiming at the collaboration being the development of 2seventy bio’s MAGE-A4 cell therapy in mainland China, Hong Kong, and Macao.
January 12, 2023
Webinar Date/Time: Tue, Jan 31, 2023 11:00 AM EST
January 11, 2023
This self-emulsifying system improves the miscibility and dispersibility of formulations in aqueous environments and may improve API solubility.
January 10, 2023
Public relations agencies dissect pharmaceutical trends: Brandwidth Solutions, Orientation Marketing and White Matter Communications